Cancer Council NSW logo
13 11 20 Information & Support
Give monthly
Menu
  • Cancer Information
    • By cancer type
      • Bowel cancer
      • Blood cancers
      • Breast cancer
      • Lung cancer
      • Melanoma
      • Prostate cancer
      • View 45 other cancers
    • General information
      • What is cancer?
      • Coping with a diagnosis
      • Cancer treatment
      • Managing side effects
      • Living well
      • Practical concerns
      • Advanced cancer
    • How can we help you?
      • Carers
      • Family and friends
      • LGBTQI+
      • Multilingual cancer information
      • Schools and teachers
    • More resources
      • Explore our new resource hub
      • Cancer Council Podcasts
      • Cancer Information Services
      • Cancer information for Aboriginal & Torres Strait Islander people
  • Get Support
    • How can we help you
      • 13 11 20 – Speak to a cancer professional
      • Connect with others
      • Cancer Counselling
      • Pro Bono Program
      • Financial Assistance
      • Transport to cancer treatment
      • Accommodation during cancer treatment
      • Support for cancer survivors
    • More information
      • Information for health professionals
      • Aboriginal & Torres Strait Islander people
      • Multilingual cancer information
      • LGBTQI+
      • Cancer and COVID-19 in NSW
      • Webinars
  • Cancer Prevention
    • By topic
      • Alcohol
      • Diet and exercise
      • Screening and early detection
      • Smoking
      • Sun protection
    • Programs
      • SunSmart NSW website
      • Improve your long game
      • Tackling Tobacco
  • Research
    • By Topic
      • Research we conduct
      • Research we fund
      • Information for researchers
      • Community Involvement in Research
    • Quick links
      • Search research by cancer type or topic
      • Research Grant Applications
      • Research Achievements
  • Get Involved
    • How will you get involved
      • Volunteer with us
      • Work with us
      • Events and Fundraising
      • Partner with us
      • Campaign with us
      • Shop with us
    • Quick Links
      • Events calendar
      • Share your story
      • Supporter Recognition
  • Donate
    • Donate today
    • Donate monthly
    • Donate in memory
    • Leave a gift in your will
    • More ways to donate
    • Donate Crypto
  • Cancer Information
    • By cancer type
      • Bowel cancer
      • Blood cancers
      • Breast cancer
      • Lung cancer
      • Melanoma
      • Prostate cancer
      • View 45 other cancers
    • General information
      • What is cancer?
      • Coping with a diagnosis
      • Cancer treatment
      • Managing side effects
      • Living well
      • Practical concerns
      • Advanced cancer
    • How can we help you?
      • Carers
      • Family and friends
      • LGBTQI+
      • Multilingual cancer information
      • Schools and teachers
    • More resources
      • Explore our new resource hub
      • Cancer Council Podcasts
      • Cancer Information Services
      • Cancer information for Aboriginal & Torres Strait Islander people
  • Get Support
    • How can we help you
      • 13 11 20 – Speak to a cancer professional
      • Connect with others
      • Cancer Counselling
      • Pro Bono Program
      • Financial Assistance
      • Transport to cancer treatment
      • Accommodation during cancer treatment
      • Support for cancer survivors
    • More information
      • Information for health professionals
      • Aboriginal & Torres Strait Islander people
      • Multilingual cancer information
      • LGBTQI+
      • Cancer and COVID-19 in NSW
      • Webinars
  • Cancer Prevention
    • By topic
      • Alcohol
      • Diet and exercise
      • Screening and early detection
      • Smoking
      • Sun protection
    • Programs
      • SunSmart NSW website
      • Improve your long game
      • Tackling Tobacco
  • Research
    • By Topic
      • Research we conduct
      • Research we fund
      • Information for researchers
      • Community Involvement in Research
    • Quick links
      • Search research by cancer type or topic
      • Research Grant Applications
      • Research Achievements
  • Get Involved
    • How will you get involved
      • Volunteer with us
      • Work with us
      • Events and Fundraising
      • Partner with us
      • Campaign with us
      • Shop with us
    • Quick Links
      • Events calendar
      • Share your story
      • Supporter Recognition
  • Donate
    • Donate today
    • Donate monthly
    • Donate in memory
    • Leave a gift in your will
    • More ways to donate
    • Donate Crypto
  • Home
  • Research
  • Redesigning testing for high-risk childhood leukaemia

Redesigning testing for high-risk childhood leukaemia

Professor Richard Lock Children’s Cancer Institute $447,650 2022-2024

Background

Acute lymphoblastic leukaemia (ALL) is the most common cancer in children and a leading cause of death from disease. After initial treatment, up to one in five children with ALL will eventually relapse and half of these patients will not survive.  

To identify which children are at high risk of relapse, clinicians collect bone marrow samples to check for any remaining residual ALL cells. This is called minimal residual disease testing, or MRD testing. Children identified as being at high risk of relapse can then receive more intensive treatment to improve their chances of survival, while children at low risk can be spared additional treatment, reducing the short- and long-term impact of side effects. 

However, MRD testing currently uses bone marrow collected and repeated sampling is an invasive procedure. While this approach is very effective, it cannot detect any residual ALL cells and or predict relapse in any other organs in the body. 

The research

Professor Lock and his team have been investigating a less invasive and more broadly effective approach to identifying children at high risk of ALL relapse to replace bone marrow sampling. If cancer cells are still present in the body after treatment, then DNA from the tumour cells will be circulating in the patient’s blood and can be detected by a technique known as liquid biopsy. Detecting very small quantities of this DNA before cancer relapse is a challenge.  

To overcome this challenge, Professor Lock and his team have joined forces with UNSW Chemist Professor Justin Gooding, who has developed an ultrasensitive technology called a ‘dispersible electrode biosensor’, capable of detecting even the smallest amounts of tumour DNA in blood. 

In this project, the multidisciplinary team will use this technology to study the dynamics of tumour DNA that is specific for each patient in blood through the cycle of ALL progression – diagnosis, remission and relapse.  

This research will pave the way for the team to develop less invasive and personalised diagnostic tests to detect residual ALL cells still present after treatment.  

The impact

This project is the starting point for implementing personalised blood testing to identify children at high risk of relapse from ALL. This ground-breaking new testing approach will lead to improved detection of the smallest of traces of cancer left behind after treatment. As the blood test is minimally invasive, clinicians will be able to test more frequently, allowing them to monitor for changes and personalise ongoing treatment options in real-time.  

The ‘dispersible electrode biosensor’ can be used to detect traces of any solid tumour. Once Professor Lock and his team have successfully developed this new diagnostic approach, it could be applied to other cancers in children and adults. 

Search research
Cancer research depends on your support
Give monthly
Share

Achievements
18 Jun 2020

Addressing the needs of long-term prostate cancer survivors

Find out more
20 May 2020

HPV vaccine linked to decline in premature births

Find out more
Latest news
08 May 2023

Personalising treatment for women with ovarian cancer

Find out more
  • About us
  • News & Media
  • Cancer Council Shop
  • Contact us
  • Work with us
  • Privacy and website policies
Aboriginal Daffodil logo

Cancer Council NSW acknowledges the traditional custodians of the land on which we live and work. We pay our respects to the elders past and present and extend that respect to all other Aboriginal and Torres Strait Islander peoples.

Registered Charity (ACNC)

© Cancer Council NSW 2021. Cancer Council NSW is registered with the Australian Taxation Office as an Income Tax Exempt Charity: Charitable Fundraising Authority No. 18521. ABN 51 116 463 846. Cancer Council NSW, 153 Dowling Street, Woolloomooloo NSW 2011. All donations over $2 are tax deductible.